Renal anemia is a common complication of chronic kidney disease (CKD). The primary goal of treatment of renal anemia is to increase and maintain Hb levels and reduce the risk of complications of chronic hypoxia, high mortality rates, and cardiovascular disease. Renal anemia nondialysis patients are initially treated with oral iron, followed by IV iron; ESAs are prescribed as third-line therapy. Dialysis patients usually receive IV iron therapy followed by ESAs. Several ESAs and iron supplements are available and have had varying degrees of commercial success. Key approved agents include Amgen’s Epogen, Janssen’s Procrit, Pfizer’s Retacrit, Amgen’s Aranesp, Roche / Chugai’s Mircera, and Akebia’s Auryxia. This report provides important insights into how these agents are used in the management of renal anemia and how practices are evolving.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key drugs: Epogen / Procrit, Retacrit, Aranesp, Mircera, Auryxia, iron supplements
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.